Open-Label Phase II Study of the Efficacy of Nivolumab for Cancer of Unknown Primary

Annals of Oncology ◽

10.1016/j.annonc.2021.11.009 ◽

2021 ◽

Author(s):

J. Tanizaki ◽

K. Yonemori ◽

K. Akiyoshi ◽

H. Minami ◽

H. Ueda ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

Cancer Of Unknown Primary ◽

Unknown Primary ◽

Open Label Phase

Download Full-text

Faculty Opinions recommendation of In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726290170.793527220 ◽

2017 ◽

Author(s):

Vincent Emery

Keyword(s):

Phase Ii ◽

Cytomegalovirus Infection ◽

Phase Ii Study ◽

In Utero ◽

Congenital Cytomegalovirus Infection ◽

Congenital Cytomegalovirus ◽

Open Label Phase

Download Full-text

MP87-11 INTERIM ANALYSIS OF AN OPEN LABEL PHASE II STUDY OF ENZALUTAMIDE AND RADIUM RA 233 DICHLORIDE IN SYMPTOMATIC, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS.

The Journal of Urology ◽

10.1016/j.juro.2018.02.2911 ◽

2018 ◽

Vol 199 (4S) ◽

Author(s):

Neal Shore ◽

Paul Schellhammer ◽

Ronald Tutrone ◽

Neil Mariados ◽

Stacey Harrelson

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Interim Analysis ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Open Label Phase

Download Full-text

179P Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin for early triple-negative breast cancer: A single-arm, open-label, phase II study

Annals of Oncology ◽

10.1016/j.annonc.2021.08.460 ◽

2021 ◽

Vol 32 ◽

pp. S436

Author(s):

C. Wang ◽

Z. Liu ◽

X. Chen ◽

J. Qiao ◽

L. Li ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Ii Study ◽

Open Label Phase

Download Full-text

A randomised, multicentre open-label phase II study to evaluate the efficacy, tolerability and pharmacokinetics of oral vinorelbine plus cisplatin versus intravenous vinorelbine plus cisplatin in Chinese patients with chemotherapy-naive unresectable or metastatic non-small cell lung cancer

Journal of Thoracic Disease ◽

10.21037/jtd.2019.08.22 ◽

2019 ◽

Vol 11 (8) ◽

pp. 3347-3359 ◽

Author(s):

Yunpeng Yang ◽

Jianhua Chang ◽

Cheng Huang ◽

Yiping Zhang ◽

Jie Wang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Chinese Patients ◽

Small Cell Lung ◽

Oral Vinorelbine ◽

Open Label Phase

Download Full-text

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study

Cancer Medicine ◽

10.1002/cam4.2423 ◽

2019 ◽

Vol 8 (12) ◽

pp. 5468-5481

Author(s):

Nobuaki Sato ◽

Norikazu Masuda ◽

Takashi Morimoto ◽

Takayuki Ueno ◽

Chizuko Kanbayashi ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Phase Ii ◽

Phase Ii Study ◽

Estrogen Receptor Positive ◽

Open Label Phase ◽

Positive Breast Cancer

Download Full-text

A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma

British Journal of Cancer ◽

10.1038/s41416-018-0051-8 ◽

2018 ◽

Vol 118 (9) ◽

pp. 1162-1168 ◽

Author(s):

D. H. Palmer ◽

Y. T. Ma ◽

M. Peck-Radosavljevic ◽

P. Ross ◽

J. Graham ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Phase I ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Hepatocellular Carcinoma ◽

Open Label Phase

Download Full-text

Methotrexate-Paclitaxel-Epirubicin-Carboplatin (M-TEC) Combination Chemotherapy in Patients with Advanced Bladder Cancer: An Open Label Phase II Study

Journal of Chemotherapy ◽

10.1179/joc.2005.17.4.444 ◽

2005 ◽

Vol 17 (4) ◽

pp. 444-448 ◽

Author(s):

N. Tsavaris ◽

C. Kosmas ◽

H. Skopelitis ◽

A. Dimitrakopoulos ◽

P. Kopteridis ◽

...

Keyword(s):

Bladder Cancer ◽

Phase Ii ◽

Combination Chemotherapy ◽

Phase Ii Study ◽

Advanced Bladder Cancer ◽

Open Label Phase

Download Full-text

900 OPEN-LABEL PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF PERSONALIZED PEPTIDE VACCINATION (PPV) IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER(CRPC)

The Journal of Urology ◽

10.1016/j.juro.2011.02.2609 ◽

2011 ◽

Vol 185 (4S) ◽

Author(s):

Masanori Noguchi ◽

Fukuko Moriya ◽

Shigetaka Suekane ◽

Kei Matsuoka ◽

Gaku Arai ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Efficacy And Safety ◽

Castration Resistant Prostate Cancer ◽

Peptide Vaccination ◽

Castration Resistant ◽

Open Label Phase

Download Full-text

Regorafenib in patients with refractory metastatic pancreatic cancer. An open-label phase II study (RESOUND)

Annals of Oncology ◽

10.1093/annonc/mdw371.84 ◽

2016 ◽

Vol 27 ◽

pp. vi233 ◽

Author(s):

S. Bozzarelli ◽

L. Rimassa ◽

L. Giordano ◽

S. Sala ◽

M.C. Tronconi ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Pancreatic Cancer ◽

Open Label Phase

Download Full-text

A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

Investigational New Drugs ◽

10.1007/s10637-018-0599-4 ◽

2018 ◽

Vol 36 (4) ◽

pp. 674-682 ◽

Author(s):

Arthur Lui ◽

Karen Mulder ◽

Christine Brezden-Masley ◽

Michael Vickers ◽

Jose Monzon ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

Gastroesophageal Junction ◽

Line Treatment ◽

Open Label Phase ◽

First Line Treatment

Download Full-text